论文部分内容阅读
目的:探讨程序性死亡配体-1(PD-L1)在鼻咽癌(NPC)中的表达及其临床意义。方法:采用免疫组织化学染色法检测59例NPC患者的癌组织和10例正常鼻咽黏膜组织中PD-L1的表达,RT-PCR技术检测30例NPC患者的癌组织及其中10例距离肿瘤组织3cm以外的正常鼻咽黏膜组织中PD-L1mRNA的表达,并对其表达水平与临床病理组织学参数之间的关系进行相关性分析。结果:正常鼻咽黏膜组织中不表达PD-L1分子,而NPC癌组织中免疫组织化学PD-L1阳性表达率为67.8%(40/59),RT-PCR检测PD-L1mRNA的阳性表达率为66.7%(20/30)。PD-L1的表达与肿瘤分期及淋巴结转移明显相关(P<0.05),但与患者的年龄、性别无明显相关(P>0.05)。结论:PD-L1NPC组织中的高表达,可能在肿瘤的发生、发展中起到一定的作用,有希望成为NPC免疫治疗的一个新靶点。
Objective: To investigate the expression of programmed death ligand-1 (PD-L1) in nasopharyngeal carcinoma (NPC) and its clinical significance. Methods: The expressions of PD-L1 in 59 cases of NPC and 10 cases of normal nasopharyngeal mucosa were detected by immunohistochemical staining. The expression of PD-L1 was detected by RT-PCR in 30 NPC patients and 10 cases of tumor tissues The expression of PD-L1mRNA in normal nasopharyngeal mucosa beyond 3cm was analyzed, and the correlation between the expression of PD-L1mRNA and the clinicopathological parameters was analyzed. Results: PD-L1 was not expressed in normal nasopharyngeal mucosa, while the positive rate of PD-L1 expression in NPC was 67.8% (40/59). The positive rate of PD-L1 mRNA detected by RT-PCR was 66.7% (20/30). The expression of PD-L1 was significantly correlated with tumor stage and lymph node metastasis (P <0.05), but not with the age and sex of patients (P> 0.05). CONCLUSION: High expression of PD-L1NPC may play a role in tumorigenesis and progression and hopefully become a new target of NPC immunotherapy.